2023
Suboptimal Sleep Duration Is Associated With Poorer Neuroimaging Brain Health Profiles in Middle‐Aged Individuals Without Stroke or Dementia
Clocchiatti‐Tuozzo S, Rivier C, Renedo D, Lopez V, Geer J, Miner B, Yaggi H, de Havenon A, Payabvash S, Sheth K, Gill T, Falcone G. Suboptimal Sleep Duration Is Associated With Poorer Neuroimaging Brain Health Profiles in Middle‐Aged Individuals Without Stroke or Dementia. Journal Of The American Heart Association 2023, 13: e031514. PMID: 38156552, PMCID: PMC10863828, DOI: 10.1161/jaha.123.031514.Peer-Reviewed Original ResearchConceptsSuboptimal sleep durationWhite matter hyperintensitiesMiddle-aged individualsLong sleep durationLarger WMH volumeSleep durationMiddle-aged adultsHealth profileWMH volumeAmerican Heart Association's LifeAsymptomatic middle-aged adultsWMH presenceVolume of WMHOptimal sleepSelf-reported sleep durationModifiable risk factorsWhite matter tractsProspective magnetic resonanceSimple 7Cardiovascular healthRisk factorsShort sleepMatter hyperintensitiesHigh riskEarly interventionImprovement in the Prediction of Cerebrovascular Events With White Matter Hyperintensity
de Havenon A, Smith E, Sharma R, Falcone G, Bangad A, Prabhakaran S, Sheth K. Improvement in the Prediction of Cerebrovascular Events With White Matter Hyperintensity. Journal Of The American Heart Association 2023, 12: e029374. PMID: 37345754, PMCID: PMC10356061, DOI: 10.1161/jaha.123.029374.Peer-Reviewed Original ResearchConceptsWhite matter hyperintensitiesIncident strokePrimary outcomeHypertensive individualsMatter hyperintensitiesAtherosclerotic cardiovascular disease risk scoreCognitive impairmentCardiovascular disease risk scoreVascular risk factorsCurrent cigarette smokingDisease risk scoreMagnetic resonance imagingLogistic regression modelsRandomization armCerebrovascular eventsVascular riskCigarette smokingPrognostic informationRisk factorsPrognostic abilityRisk scoreCognitive declineResonance imagingDeLong testStrokeIdentification of White Matter Hyperintensities in Routine Emergency Department Visits Using Portable Bedside Magnetic Resonance Imaging
de Havenon A, Parasuram N, Crawford A, Mazurek M, Chavva I, Yadlapalli V, Iglesias J, Rosen M, Falcone G, Payabvash S, Sze G, Sharma R, Schiff S, Safdar B, Wira C, Kimberly W, Sheth K. Identification of White Matter Hyperintensities in Routine Emergency Department Visits Using Portable Bedside Magnetic Resonance Imaging. Journal Of The American Heart Association 2023, 12: e029242. PMID: 37218590, PMCID: PMC10381997, DOI: 10.1161/jaha.122.029242.Peer-Reviewed Original ResearchConceptsWhite matter hyperintensitiesMagnetic resonance imagingSevere white matter hyperintensitiesConventional magnetic resonance imagingResonance imagingRetrospective cohortEmergency departmentMatter hyperintensitiesVascular risk factorsProspective observational studyVascular cognitive impairmentTesla magnetic resonance imagingArea Deprivation IndexProspective cohortAdult patientsAcute careRisk factorsCardiovascular diseaseObservational studyCognitive impairmentPatientsCare magnetic resonance imagingIntermodality agreementCohortDeprivation index
2022
Statin Usage Increases White Matter Hyperintensities
Goldstein ED, Garg G, Navarro K, Wolcott Z, Yaghi S, Wong KH, McLean K, de Havenon AH. Statin Usage Increases White Matter Hyperintensities. The Neurologist 2022, 28: 94-98. PMID: 35680399, DOI: 10.1097/nrl.0000000000000448.Peer-Reviewed Original ResearchConceptsWhite matter hyperintensitiesWMH progressionStatin usageTop tertileRisk factorsMatter hyperintensitiesWMH volumeConventional cerebrovascular risk factorsProgression of WMHCerebral small vessel diseaseInfluence of dyslipidemiaCerebrovascular risk factorsInfluence of statinsBaseline WMH volumeSmall vessel diseaseSynergistic risk factorsLow-density lipoproteinFull therapyStatin useVessel diseaseStudy visitWMH developmentPartial therapyWMH dataReductase inhibitors
2021
Association Between Cardiac Magnetic Resonance Imaging Parameters and White Matter Hyperintensities (2870)
Navarro K, Garg G, Wolcott Z, Muddasani V, Peterson C, Sheibani N, Wong K, Ibrahim M, de Havenon A, Goldstein E. Association Between Cardiac Magnetic Resonance Imaging Parameters and White Matter Hyperintensities (2870). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.2870.Peer-Reviewed Original Research
2019
Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities?
de Havenon A, Prabhakaran S, Turan T, Gottesman R, Yeatts S, Rost N. Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities? Journal Of Stroke And Cerebrovascular Diseases 2019, 28: 104371. PMID: 31495669, PMCID: PMC8015436, DOI: 10.1016/j.jstrokecerebrovasdis.2019.104371.Peer-Reviewed Original ResearchMeSH KeywordsAntihypertensive AgentsAsymptomatic DiseasesAttitude of Health PersonnelDisease ProgressionHealth Care SurveysHealth Knowledge, Attitudes, PracticeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLeukoencephalopathiesNeurologistsPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Therapeutic EquipoiseTreatment OutcomeConceptsAsymptomatic white matter hyperintensitiesWhite matter hyperintensitiesOptimal medical treatmentMatter hyperintensitiesMedical treatmentCognitive impairmentIntensive Blood Pressure ReductionNeurologists' attitudesBlood pressure targetsStroke prevention therapyBlood pressure reductionOptimal medical managementRegional coordinating centersMild cognitive impairmentStatin therapyIschemic strokeMicrovascular diseasePressure targetsPrevention therapyClinical outcomesFunctional disabilityMedical managementPatient populationCommon manifestationWMH progressionSubclinical Cerebrovascular Disease: Epidemiology and Treatment
de Havenon A, Meyer C, McNally JS, Alexander M, Chung L. Subclinical Cerebrovascular Disease: Epidemiology and Treatment. Current Atherosclerosis Reports 2019, 21: 39. PMID: 31350593, PMCID: PMC8011954, DOI: 10.1007/s11883-019-0799-1.Peer-Reviewed Original ResearchConceptsMedical managementRisk factorsAggressive medical managementSilent brain infarctsOptimal medical treatmentVascular risk factorsDevelopment of dementiaBest medical managementImportant risk factorLate-life depressionCommon clinical scenariosWhite matter hyperintensitiesT2-weighted MRISusceptibility-weighted MRIEvidence-based approachBrain infarctsCerebral microbleedsCerebrovascular diseaseGait instabilityBrain healthClinical equipoiseWorse outcomesClinical trialsMatter hyperintensitiesEpidemiologic studiesBlood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics
de Havenon A, Majersik JJ, Tirschwell DL, McNally JS, Stoddard G, Rost NS. Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics. Neurology 2019, 92: e1168-e1175. PMID: 30737332, PMCID: PMC6511110, DOI: 10.1212/wnl.0000000000007093.Peer-Reviewed Original ResearchConceptsType 2 diabeticsBlood pressureWhite matter hyperintensitiesRandomization armGlycemic controlWMH progressionHigher systolic blood pressureWhite matter hyperintensity progressionIntensive blood pressureBlood pressure controlSystolic blood pressureHigh blood pressureType 2 diabetesACCORD-MINDComorbid diabetesMacrovascular complicationsCardiovascular riskHemoglobin A1cPrimary outcomeControl armMatter hyperintensitiesAggressive approachWMH volumeControl interventionsPressure control